Welcome to our dedicated page for OMEROS SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OMEROS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OMEROS's regulatory disclosures and financial reporting.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,961,792 shares of Omeros Corp common stock. This position represents 8.2% of the outstanding common shares.
BlackRock reports sole voting power over 5,835,368 shares and sole dispositive power over 5,961,792 shares, with no shared voting or dispositive power. Various underlying clients and funds have economic interests in these shares, but no single person has more than five percent of Omeros’ total outstanding common stock.
Omeros Corporation reported that Chairman, CEO & President Gregory A. Demopulos received a grant of 1,000,000 stock options on July 22, 2026. The options have an exercise price of $9.84 per share, expire on July 22, 2036, and are exercisable into an equal number of common shares.
According to the vesting schedule, one-third of the options vest and become exercisable on August 1, 2027, with the remaining options vesting in 32 equal monthly installments on the first day of each month thereafter. Following this grant, he directly holds stock options for 1,000,000 shares.
Omeros Corp granted VP and General Counsel Peter B. Cancelmo 105,000 stock options for common stock on July 22, 2026. The options have a $9.84 per-share exercise price and expire on July 22, 2036. One-third vests on August 1, 2027, with the remaining shares vesting in 32 equal monthly installments thereafter.
Omeros Corp reported that its VP, Finance & CAO, David J. Borges received a grant of 105,000 stock options for common stock at an exercise price of $9.84 per share, expiring on July 22, 2036. One-third vests on August 1, 2027, with the remainder vesting in 32 equal monthly installments thereafter.
Omeros Corporation reports that on July 20, 2026 it completed the repurchase of approximately $14.5 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 under previously disclosed privately negotiated agreements. The total purchase price, inclusive of accrued and unpaid interest and all other obligations, was approximately $29.0 million. Omeros had previously repurchased $16.0 million principal amount of the same Notes from the same holders. In total, the company has now repurchased and retired $30.5 million aggregate principal amount of these Notes, with approximately $40.3 million principal amount remaining outstanding.
Omeros Corporation is repurchasing a portion of its 9.50% Convertible Senior Notes due 2029 and has agreed to buy more. The company expects to complete the repurchase of $16.0 million aggregate principal amount of Notes on July 6, 2026, for a total purchase price of approximately $31.3 million. After this step, about $54.8 million aggregate principal amount of Notes will remain outstanding.
On July 2, 2026, Omeros also agreed to repurchase additional Notes with an aggregate principal amount of up to approximately $14.5 million for a total purchase price of up to approximately $31.0 million, with pricing tied to an averaging period beginning July 6, 2026. If fully completed, these additional repurchases would leave approximately $40.3 million aggregate principal amount of Notes outstanding, and the company may seek unsecured or limited-collateral debt financing to replace some or all of the cash used.
Omeros Corporation reported the results of its 2026 Annual Meeting of Shareholders held on June 18, 2026. Shareholders of record were entitled to vote 72,168,330 common shares, and 58,010,900 shares were represented in person or by proxy, an 80.04% turnout. The filing lists detailed vote totals for the election of directors, including 20,787,774 shares voted for Thomas J. Cable and 10,531,585 against, and 25,314,641 for Peter A. Demopulos, M.D. and 6,063,216 against. It also provides final for/against/abstain and broker non-vote counts for additional shareholder proposals.
Omeros Corporation director Rajiv Shah received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $10.28 per share and expire on June 17, 2036. The award was made under Omeros’ non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The option will fully vest and become exercisable on the day before the company’s 2027 annual shareholder meeting, as long as Shah continues serving as a director through that date. Following this grant, he holds 15,000 stock options directly.
OMEROS CORP director Diana T. Perkinson received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $10.28 per share and were awarded under the company’s non-employee director compensation policy in connection with the June 18, 2026 annual shareholder meeting.
The option grant will fully vest and become exercisable on the day before the 2027 annual shareholder meeting, as long as she continues serving as a director through that date. Following this award, she holds 15,000 stock options directly.
OMEROS CORP director Leroy E. Hood received a routine stock option grant as part of non-employee director compensation. He was granted options to buy 15,000 shares of common stock at an exercise price of $10.28 per share, expiring on June 17, 2036. The option will fully vest and become exercisable on the day before the 2027 annual meeting of shareholders, provided he continues to serve as a director through that date.